Doldavipron Hydrochloride (OP-10)
Not specified (rare disease)
Regulatory ReviewOrphan Drug & Priority Review designated
Key Facts
Indication
Not specified (rare disease)
Phase
Regulatory Review
Status
Orphan Drug & Priority Review designated
Company
About Ohara Pharmaceutical
Japanese pharma company developing innovative and generic drugs for oncology, hepatology, and CNS disorders.
View full company profile